drugset / Trial / NCT05215015
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia
Phase 0
Unknown
18 enrolled
Wuxi People's Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, nonrandomized, investigator-initiated clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of anti-CD33/CLL1 CAR-NK cell injection in patients with acute myeloid leukemia (AML), and to determine PK parameters, maximum tolerated dose (MTD), and phase II recommended dose (RP2D) for subjects receiving CAR-NK cell injection.
Timeline
- Start
- 2020-11-30
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD33/CLL1 CAR-NK Cells | Cell therapy | 3 cells | — |